The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

A process for the continuous preparation of 1,2-propylenediamine (1,2-PDA) and dimethyldiethylenetriamine (DMDETA) via reaction of monoisopropanolamine (MIPOA) with ammonia in the presence of hydrogen and a supported heterogeneous hydrogenation catalyst (catalyst), wherein the reaction is effected in the liquid phase at an absolute pressure in the range from 60 to 170 bar.

A process for the continuous preparation of 1,2-propylenediamine (1,2-PDA) and dimethyldiethylenetriamine (DMDETA) via reaction of monoisopropanolamine (MIPOA) with ammonia in the presence of hydrogen and a supported heterogeneous hydrogenation catalyst (catalyst), wherein the reaction is effected in the liquid phase at an absolute pressure in the range from 60 to 170 bar.

The invention is a herbicidal composition containing an alkanolamine salt of an dicamba capable of remaining as a single phase liquid over a period of at least 1 week and containing low amounts of water and high loadings of the salt. Such herbicidal compositions are capable of remaining liquid in the absence of high amounts of water, thereby enhancing their capacity to remain liquid over an extended period of time when exposed to environmental conditions to improve their effectiveness to transport the active salt through a leafy substrate and can reduce transportation costs by increasing the salt loading without compromising the stability of the composition.

The invention is a herbicidal composition containing an alkanolamine salt of an dicamba capable of remaining as a single phase liquid over a period of at least 1 week and containing low amounts of water and high loadings of the salt. Such herbicidal compositions are capable of remaining liquid in the absence of high amounts of water, thereby enhancing their capacity to remain liquid over an extended period of time when exposed to environmental conditions to improve their effectiveness to transport the active salt through a leafy substrate and can reduce transportation costs by increasing the salt loading without compromising the stability of the composition.

A process for the continuous preparation of 1,2-propylenediamine (1,2-PDA) and dimethyldiethylenetriamine (DMDETA) via reaction of monoisopropanolamine (MIPOA) with ammonia in the presence of hydrogen and a supported heterogeneous hydrogenation catalyst (catalyst), wherein the reaction is effected in the liquid phase at an absolute pressure in the range from 60 to 170 bar.

A process for the continuous preparation of 1,2-propylenediamine (1,2-PDA) and dimethyldiethylenetriamine (DMDETA) via reaction of monoisopropanolamine (MIPOA) with ammonia in the presence of hydrogen and a supported heterogeneous hydrogenation catalyst (catalyst), wherein the reaction is effected in the liquid phase at an absolute pressure in the range from 60 to 170 bar.